Constantinos Alifieris

Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma

Dimitrios T. Trafalis, Constantinos Alifieris, Anastasios Kalantzis et al. · Journal of Immunotherapy · 2018 · 47 citations

Urology, Radiation Therapy, Anti-pd-1 Mab Nivolumab +13

Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.

George D. Geromichalos, Constantinos Alifieris, Elena Geromichalou et al. · PubMed · 2017 · 31 citations

Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study

Ekaterini Christina Tampaki, Athanasios Tampakis, Constantinos Alifieris et al. · Clinical Drug Investigation · 2018 · 30 citations

Breast Oncology, Medicine, Cancer Management +9

Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer

Dimitrios T. Trafalis, Constantinos Alifieris, George P. Stathopoulos et al. · Cancer Chemotherapy and Pharmacology · 2016 · 21 citations

Medicine, Pharmacology, Phase Ii Study +5

Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas

Constantinos Alifieris, John Grınıatsos, Spiros Delis et al. · American Journal of Clinical Oncology · 2020 · 14 citations